Passive Immunity Trial for Our Neighbors (PassITON): A randomized, placebo-controlled multi-site trial of anti-SARS-CoV-2 convalescent plasma to treat hospitalized adults with COVID-19

范德比尔特临床与翻译研究所(VICTR)是一家功能强大的 以及集成的临床和翻译(C&T)研究基础设施，提高了质量 范德比尔特及其长期合作伙伴Meharry进行的研究的科学严谨性， 这是美国历史上最古老的黑人学术健康科学机构。卢旺达问题国际法庭将为 CTSA计划的使命是利用以下方面的独特资源和专业知识 卢旺达问题国际法庭的中心具有以下目标：1)利用卢旺达问题国际法庭强大的协作能力 团队科学方法论，推动跨学科研究方法，并整合 在研究的所有阶段向利益相关者证明了社区参与原则；2)制定、 实施和传播信息学和数据组织方法，以传播研究 效率、质量和准备，并将数据收集整合到务实的行为中 试验；3)确保翻译科学员工队伍多样化，并拥有技能、知识、 以及推进发现成果转化所需的资源；4)显著改善 通过加强和系统地提高科技研究的效率、质量和代表性 整合支持最高质量研究启动和实施的服务和计划； 5)与以下机构合作，显著提高多点临床试验的效率和质量 TICS和RICS，通过利用集中的监管和法律协议，提供快速 可行性和招募方法和实践，以及创建和传播新的临床 试验设计和方法；以及6)利用独特的优势利用新资源 BioVU和Phewas用于指导药物开发和再利用。

The Vanderbilt Institute for Clinical and Translational Research (VICTR) is a highly functional and integrated clinical and translational (C&T) research infrastructure that has raised the quality and scientific rigor of the research conducted at Vanderbilt and longstanding partner Meharry, the nation's oldest historically black academic health science institution. VICTR will contribute to the mission of the CTSA program while leveraging unique resources and expertise within VICTR's Hub with these aims: 1) Leverage VICTR's strong collaborative energy to enhance team science methodologies that propel transdisciplinary research approaches, and integrate proven community engagement principles to stakeholders for all stages of research; 2) Develop, implement and disseminate informatics and data organization methods to promulgate research efficiency, quality, and preparedness and integrate data collection in the conduct of pragmatic trials; 3) Ensure the translational science workforce is diverse and has the skills, knowledge, and resources necessary to advance translation of discoveries; 4) Measurably improve the efficiency, quality, and representativeness of C&T studies by enhancing and systematically integrating services and programs that support highest quality research initiation and conduct; 5) Measurably improve the efficiency and quality of multi-site clinical trials, in collaboration with the TICs and RICs, by leveraging centralized regulatory and legal agreements, providing rapid feasibility and recruitment methods and practices, and creating and disseminating novel clinical trial designs and methodologies; and 6) Utilize unique strengths leveraging novel resources BioVU and PheWAS to guide drug development and repurposing.